Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence

Luciene Borges, Vanessa K. P. Oliveira, June Baik, Sean C. Bendall, Rita C. R. Perlingeiro

Blood (2019) 133 (7): 688–696.

https://doi.org/10.1182/blood-2018-09-874677

Published: 2019

Includes: Supplemental data

Journal Articles

MYC-ID3 Pathway in a Cohort of Diffuse Large B Cell Lymphomas: Immunoistochemical Analysis and Prognostic Implications

Elisa Doni, MD, Fabio Pagni, MD, Fausto Rossini, MD, Angelo Belotti, MD, Silvia Bolis, MD, Ivana Casaroli, MD, Giorgio Cattoretti, MD, Pietro Enrico Pioltelli, MD, Carlo Gambacorti-Passerini, MD

Blood (2016) 128 (22): 5310.

https://doi.org/10.1182/blood.V128.22.5310.5310

Published: 2016

Journal Articles

Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization

Maurizio Di Liberto, Ph.D., Xiangao Huang, Ph.D., Jamieson Bretz, Ph.D., Scott A Ely, M.D., Rediet Zewdu, B.S., David Jayabalan, B.S.M.S, Suzhen Chen, B.S., Christopher J Kirk, Ph.D., Sophia Randolph, M.D., Ph.D., Ruben Niesvizky, M.D., Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2010) 116 (21): 2989.

https://doi.org/10.1182/blood.V116.21.2989.2989

Published: 2010

Journal Articles

Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4

Xiangao Huang, Ph.D., Maurizio Di Liberto, Ph.D., David Jayabalan, B.S.M.S, Mohamad Hussein, M.D., Sophia Randolph, M.D., Ph.D., Ruben Niesvizky, M.D., Selina Chen-Kiang, Ph.D.

Blood (2010) 116 (21): 449.

https://doi.org/10.1182/blood.V116.21.449.449

Published: 2010

Journal Articles

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Rediet Zewdu, B.S., Francesco Parlati, PhD, Monette Aujay, B.S., Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 2854.

https://doi.org/10.1182/blood.V114.22.2854.2854

Published: 2009

Journal Articles

Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development

Katy J. McCann, Margaret Ashton-Key, KellyAnn Smith, Freda K. Stevenson, Christian H. Ottensmeier

Blood (2009) 113 (19): 4677–4680.

https://doi.org/10.1182/blood-2008-09-179366

Published: 2009

Includes: Supplemental data

Journal Articles

Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047

Xiangao Huang, PhD, Kathryn Bailey, Maurizio Di Liberto, PhD, Francesco Parlati, PhD, Ruben Niesvizky, MD, Susan Demo, PhD, Selina Chen-Kiang, PhD

Blood (2008) 112 (11): 3670.

https://doi.org/10.1182/blood.V112.11.3670.3670

Published: 2008

Journal Articles

Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.

Xiangao Huang, PhD, Tracey Louie, B.Sc., Maurizio Di Liberto, Ph.D., Jun Rice, Ph.D., David Jayabalan, B.Sc., Kang Zhang, B.Sc., Michael Palladino, Ph.D., Isan Chen, M.D., Peter Toogood, Ph.D, Ruben Niesvizky, M.D., Malcolm A.S. Moore, Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2007) 110 (11): 667.

https://doi.org/10.1182/blood.V110.11.667.667

Published: 2007

Journal Articles

Combination of Transplantation of Haploidentical Human Mesenchymal Stem Cells and Rituximab Therapy in a Patient with Extensive Therapy-Refractory Chronic Graft Versus Host Disease.

L. Mueller, M. Christopeit, J. Luetzkendorf, K. Reichelt, E. Schlesinger, M. Schulze, G. Behre

Blood (2006) 108 (11): 5290.

https://doi.org/10.1182/blood.V108.11.5290.5290

Published: 2006

Journal Articles

Incidence of HCV and HIV NAT Positive in Cord Blood Donors.

Jennifer Rhamy, MBA, MA, MT(ASCP)SBB, Mark Beltz, MT(ASCP), Karla John, MT(ASCP), David Feria, BS, Dan Waxman, MD, Robert Dracker, MD

Blood (2005) 106 (11): 1900.

https://doi.org/10.1182/blood.V106.11.1900.1900

Published: 2005

Journal Articles

Mutually Exclusive Cdk4-Cyclin D1 and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.

Scott Ely, MD, MPH, Maurizio Di Liberto, PhD, Ruben Niesvizky, MD, Eunice Hatada, PhD, Hearn Cho, MD, PhD, Daniel M. Knowles, MD, Joseph Lane, MD, Selina Chen-Kiang, PhD

Blood (2005) 106 (11): 501.

https://doi.org/10.1182/blood.V106.11.501.501

Published: 2005

Journal Articles

Variability of Proliferative Patterns in Acute Lymphoid Leukemia of Children

Hans P. Wagner, M.D., Hans Cottier, M.D., Eugene P. Cronkite, M.D.

Blood (1972) 39 (2): 176–186.

https://doi.org/10.1182/blood.V39.2.176.176

Published: 1972

NARROW

Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence

MYC-ID3 Pathway in a Cohort of Diffuse Large B Cell Lymphomas: Immunoistochemical Analysis and Prognostic Implications

Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization

Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development

Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047

Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.

Combination of Transplantation of Haploidentical Human Mesenchymal Stem Cells and Rituximab Therapy in a Patient with Extensive Therapy-Refractory Chronic Graft Versus Host Disease.

Incidence of HCV and HIV NAT Positive in Cord Blood Donors.

Mutually Exclusive Cdk4-Cyclin D1 and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.

Variability of Proliferative Patterns in Acute Lymphoid Leukemia of Children

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only